| Literature DB >> 26990533 |
Ian Weidling1,2, Russell H Swerdlow1,2,3,4.
Abstract
This Editorial highlights a study by Singh and coworkers in the current issue of Journal of Neurochemistry, in which the authors present additional evidence that AMPKα1 is reduced in X-linked adrenoleukodystrophy (X-ALD). They make a case for increasing AMPKα1 activity for therapeutic purposes in this disease, and indicate how this goal may be achieved. Read the highlighted article 'Metformin-induced mitochondrial function and ABCD2 up regulation in X-linked adrenoleukodystrophy involves AMP activated protein kinase' on page 86.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26990533 PMCID: PMC5858159 DOI: 10.1111/jnc.13594
Source DB: PubMed Journal: J Neurochem ISSN: 0022-3042 Impact factor: 5.372